Skip to main content
NCBI home page
ACS Medicinal Chemistry Letters logoLink to ACS Medicinal Chemistry Letters
. 2019 Feb 7;10(3):389–392. doi: 10.1021/acsmedchemlett.8b00579

Atorvastatin (Lipitor) by MCR

Tryfon Zarganes-Tzitzikas 1, Constantinos G Neochoritis 1, Alexander Dömling 1,*
PMCID: PMC6421582  PMID: 30891146

Abstract

graphic file with name ml-2018-00579v_0004.jpg

A concise and convergent synthesis of the atorvastatin, the best-selling cardiovascular drug of all time, is presented. Our approach is based on an Ugi reaction, which shortens the current synthetic route and is advantageous over the published syntheses.

Keywords: Atorvastatin, Ugi reaction, münchnone, convergent synthesis, generics

Multicomponent reactions (MCRs) are an advanced class of organic reactions which, opposite to classical organic reactions, allow for the easy, fast, and efficient generation of chemical diversity in just one assembly step.1−3 These features make them an attractive area in research and development.4 Surprisingly, the number of applications in drug discovery is rather limited regarding the superb advantages of this chemistry.5 An analysis of the currently marketed drugs, however, shows that approximately 5% can be synthesized with the use of MCR, even so they are synthesized by a classical sequential pathway.6 Examples of drugs synthesized by MCR clearly show the immense advantages of them in this context, e.g., lidocaine,7 praziquantel,8,9 telaprevir,10 olanzapine,11 clopidogrel,12 lacosamide,13 carfentanil,14 ivosidenib,15 and levetiracetam (Figure 1).16 Epelsiban17 and almorexant18 are examples of compounds currently or recently in clinical trials and actually synthesized by utilization of the MCR repertoire (Figure 1).

Figure 1.

Figure 1

Open in a new tab

Examples of marketed drugs and drugs in clinical trials which have been discovered using MCR chemistry; the amine, aldehyde, isocyanide, and acid components are depicted with green, red, blue, and magenta color, respectively.

Here we report an MCR-based synthesis of atorvastatin (common trade name: Lipitor), one of the world’s best-selling medication of all time. Only in 2005, Lipitor made $12 billion in sales and was used by more than 45 million people worldwide.19 It belongs to the drug class of statins, lipid-lowering drugs for the prevention of events associated with cardiovascular disease.20 It is an example of a competitive HMG-CoA-reductase inhibitor, which consists of a pentasubstituted pyrrole core. The importance of atorvastatin until today21−23 led to much interest in its synthesis. The main retrosynthetic scheme of the atorvastatin synthesis as described in literature focuses on the assembly of its five different substituents on a pyrrole hub.24,25 By this way, which consists also the industrial route,26 the pyrrole ring could be formed by a Paal–Knorr cyclocondensation27,28 of the highly substituted 1,4-diketone 2 with primary amine 3 (Paal–Knorr route, Scheme 1, blue color).21,22,26,29−34 In 2015, a total synthesis of atorvastatin via a late-stage, regioselective 1,3-dipolar münchnone cycloaddition35 of the amido acid 4 with the acetylene derivative 5 (münchnone route, Scheme 1, red color) was described.36 Although this synthesis provided a nice solution to the problem of regioselectivity of the cycloaddition,30 the synthesis of derivative 4 required five sequential steps which contributed to eight steps for the total synthesis of atorvastatin. Regarding the latter approach, we envisioned the synthesis of the amido acid 4 in only two steps utilizing the Ugi four-component reaction (U-4C, Scheme 2).

Scheme 1. Main Retrosynthetic Scheme for the Synthesis of Atorvastatin (Paal–Knorr Route, Blue Color); A Novel Approach to the Intermediate 4 Is Proposed by MCR (Münchnone Route, Red Color).

Scheme 1

Open in a new tab

Scheme 2. MCR-Based Synthesis of 4 and the Subsequent Synthesis Towards Atorvastatin 1.

Scheme 2

Open in a new tab

The initial derived MCR adduct can be considered as a synthetic hub to a vast diversity of other scaffolds.2 Thus, the 1,4 amido acid motif could easily be derived from an Ugi adduct with the cleavage of the isocyanide moiety (Scheme 2).37,38 Indeed, the reaction at rt of p-fluorobenzaldehyde 6, the suitably functionalized, commercially available amine 3,29,39−41 the convertible isocyanide 7,42−45 and isobutyric acid 8 in 2,2,2-trifluoroethanol (TFE) afforded the Ugi adduct (U-4C) 9 in 40% yield. The choice of the corresponding isocyanide was the easiness of its cleavage at basic pH, keeping intact the other functional groups. Thus, in a one-pot acid deprotection and isocyanide cleavage, we obtained the valuable intermediate 4 in a dr 5:4 in 87% yield. Then, we performed the regioselective [3 + 2] cycloaddition36 of 4 with the N,3-diphenylpropiolamide 5 and N,N′-diisopropylcarbodiimide (DIPC) in THF, yielding the advanced intermediate 10 in 46% yield which can be readily converted by acidic deprotection with 10-camphorsulfonic acid (CSA) to atorvastatin 1 (Scheme 2).

The industrial atorvastatin synthesis via the Paal–Knorr route is a synthesis consisting of six steps excluding the synthesis of amine 3, which is commercially available (Table 1). MCR chemistry has also been employed in order to improve and optimize this synthetic route. These modifications include a one-pot Stetter/Paal–Knorr reaction sequence catalyzed by NHC46 or a Hantzsch pyrrole synthesis (Table 1).47 Regarding the münchnone route, this is the first time to the best of our knowledge, that MCR chemistry is utilized. On the basis of MCR chemistry, we synthesized the intermediate 4 in only two steps, and with two additional steps, we successfully obtained atorvastatin (Scheme 2). The Ugi reaction was performed at 10 mmol scale, see Supporting Information).

Table 1. Comparison of the Most Important, Recent Atorvastatin Syntheses in Literature along with Our MCR Approach.

  routes reference/report steps remarks
1 Paal–Knorr (22,34,29)a 6b different variations on the synthesis of amine 3/differentiation in the amine vector of the pyrrole core
2   (40) 8 differentiation in the amine vector of the pyrrole core
3   (23) 10 differentiation in the amine vector of the pyrrole core
4 Stetter/Paal–Knorr (46) 4b,c NHC-catalyzed Stetter/Paal–Knorr sequence
5 Hantzsch (47) 5d Hantzsch variation of the pyrrole synthesis
6 Münchnone (36) 7  
7   this work 4  
Open in a new tab
a

The corresponding methyl ester of the amine 3 was employed in the Paal–Knorr

b

Excluding the steps required for the synthesis of amine 3

c

The final product of the synthesis is the fully protected atorvastatin.

d

The final product of the synthesis is the atorvastatin lactone.

Our current approach effectively reduces the number of steps toward atorvastatin to only four compared with the seven reported in literature and establish this methodology equally or even better than the Paal–Knorr route. We can classify the recent syntheses of atorvastatin in four different routes (Table 1). Most of the published Paal–Knorr route syntheses include different variations of the synthesis of the amine (entry 1) or differentiation in the amine vector of the pyrrole core (entries 1–3). The required steps vary from six to 10. A Stetter/Paal–Knorr reaction sequence (entry 4) and a Hantzsch pyrrole synthesis (entry 5) were presented as alternatives with four and five steps, respectively. Our synthetic strategy can be ranked among the most competitive one with four steps (entry 7).48

It is noteworthy that our current synthetic methodology of utilizing an MCR adduct bears convertible isocyanides, yielding the 1,4-amido acid motif. This strategy is beneficial not only because we have a faster access to atorvastatin but also by this way more derivatives are accessible. Thus, we can readily synthesize substituted bioactive pyrroles with a great diversity on substituents in 1-, 2-, and 5-positions, for example, positron emission tomography (PET) labeled derivatives.36

Glossary

Abbreviations Used

TFE

2,2,2-trifluoroethanol

DIPC

N,N′-diisopropylcarbodiimide

CSA

10-camphorsulfonic acid

DCM

dichloromethane

PET

positron emission tomography.

Supporting Information Available

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acsmedchemlett.8b00579.

  • Experimental procedures and full characterization for compounds (PDF)

Author Contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

This research has been supported to (AD) by the National Institute of Health (NIH) (2R01GM097082-05), the European Lead Factory (IMI) under grant agreement number 115489, the Qatar National Research Foundation (NPRP6-065-3-012). Moreover funding was received through ITN “Accelerated Early stage drug dIScovery” (AEGIS, grant agreement no. 675555) and COFUNDs ALERT and PROMINENT (grant agreements no. 665250 and 754425), Hartstichting (ESCAPE-HF, 2018B012) and KWF Kankerbestrijding grant (grant agreement no. 10504).

The authors declare no competing financial interest.

Supplementary Material

ml8b00579_si_001.pdf (520.8KB, pdf)

References

  1. Dömling A.; Wang W.; Wang K. Chemistry and Biology Of Multicomponent Reactions. Chem. Rev. 2012, 112, 3083–3135. 10.1021/cr100233r. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Dömling A. Recent Developments in Isocyanide Based Multicomponent Reactions in Applied Chemistry. Chem. Rev. 2006, 106, 17–89. 10.1021/cr0505728. [DOI] [PubMed] [Google Scholar]
  3. Dömling A.; Ugi I. Multicomponent Reactions with Isocyanides. Angew. Chem., Int. Ed. 2000, 39, 3168–3210. . [DOI] [PubMed] [Google Scholar]
  4. Cioc R. C.; Ruijter E.; Orru R. V. A. Multicomponent Reactions: Advanced Tools for Sustainable Organic Synthesis. Green Chem. 2014, 16, 2958–2975. 10.1039/C4GC00013G. [DOI] [Google Scholar]
  5. Brown D. G.; Boström J. Analysis of Past and Present Synthetic Methodologies on Medicinal Chemistry: Where Have All the New Reactions Gone?. J. Med. Chem. 2016, 59, 4443–4458. 10.1021/acs.jmedchem.5b01409. [DOI] [PubMed] [Google Scholar]
  6. Zarganes-Tzitzikas T.; Dömling A. Modern Multicomponent Reactions for Better Drug Syntheses. Org. Chem. Front. 2014, 1, 834–837. 10.1039/C4QO00088A. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Ugi I.; Steinbrückner C. Über Ein Neues Kondensations-Prinzip. Angew. Chem. 1960, 72, 267–268. 10.1002/ange.19600720709. [DOI] [Google Scholar]
  8. Dömling A.; Khoury K. Praziquantel and Schistosomiasis. ChemMedChem 2010, 5, 1420–1434. 10.1002/cmdc.201000202. [DOI] [PubMed] [Google Scholar]
  9. Cao H.; Liu H.; Dömling A. Efficient Multicomponent Reaction Synthesis of the Schistosomiasis Drug Praziquantel. Chem. - Eur. J. 2010, 16, 12296–12298. 10.1002/chem.201002046. [DOI] [PubMed] [Google Scholar]
  10. Znabet A.; Polak M. M.; Janssen E.; de Kanter F. J. J.; Turner N. J.; Orru R. V. A.; Ruijter E. A Highly Efficient Synthesis of Telaprevir by Strategic Use of Biocatalysis and Multicomponent Reactions. Chem. Commun. 2010, 46, 7918–7920. 10.1039/c0cc02823a. [DOI] [PubMed] [Google Scholar]
  11. Gewald K.; Schinke E.; Böttcher H. Heterocyclen Aus CH-Aciden Nitrilen, VIII. 2-Amino-Thiophene Aus Methylenaktiven Nitrilen, Carbonylverbindungen Und Schwefel. Chem. Ber. 1966, 99, 94–100. 10.1002/cber.19660990116. [DOI] [Google Scholar]
  12. Gurbel P. A.; O’Connor C. M.; Cummings C. C.; Serebruany V. L. Clopidogrel: The Future Choice for Preventing Platelet Activation during Coronary Stenting?. Pharmacol. Res. 1999, 40, 107–111. 10.1006/phrs.1999.0478. [DOI] [PubMed] [Google Scholar]
  13. Wehlan H.; Oehme J.; Schäfer A.; Rossen K. Development of Scalable Conditions for the Ugi Reaction—Application to the Synthesis of (R)-Lacosamide. Org. Process Res. Dev. 2015, 19, 1980–1986. 10.1021/acs.oprd.5b00228. [DOI] [Google Scholar]
  14. Váradi A.; Palmer T. C.; Haselton N.; Afonin D.; Subrath J. J.; Le Rouzic V.; Hunkele A.; Pasternak G. W.; Marrone G. F.; Borics A.; et al. Synthesis of Carfentanil Amide Opioids Using the Ugi Multicomponent Reaction. ACS Chem. Neurosci. 2015, 6, 1570–1577. 10.1021/acschemneuro.5b00137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Popovici-Muller J.; Lemieux R. M.; Artin E.; Saunders J. O.; Salituro F. G.; Travins J.; Cianchetta G.; Cai Z.; Zhou D.; Cui D.; et al. Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1Mutant Cancers. ACS Med. Chem. Lett. 2018, 9, 300–305. 10.1021/acsmedchemlett.7b00421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Cioc R.; Schaepkens van Riempst L.; Schuckman P.; Ruijter E.; Orru R. Ugi Four-Center Three-Component Reaction as a Direct Approach to Racetams. Synthesis 2017, 49, 1664–1674. 10.1055/s-0036-1588672. [DOI] [Google Scholar]
  17. Borthwick A. D.; Liddle J.. Retosiban and Epelsiban: Potent and Selective Orally Available Oxytocin Antagonists. In Protein–Protein Interactions in Drug Discovery; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, 2013; pp 225–256. [Google Scholar]
  18. Aissaoui H.; Cappi M.; Clozel M.; Fischli W.; Ralf K.. 1,2,3,4-Tetrahydroisoquinoline Derivatives. World Patent WO2001068609A120010920, 2000.
  19. Simons J.The $10 Billion Pill Hold the Fries, Please. Lipitor, the Cholesterol-Lowering Drug, Has Become the Bestselling Pharmaceutical in History. Here’s How Pfizer Did It. Fortune January 20, 2003. [Google Scholar]
  20. Collins R.; Reith C.; Emberson J.; Armitage J.; Baigent C.; Blackwell L.; Blumenthal R.; Danesh J.; Smith G. D.; DeMets D.; et al. Interpretation of the Evidence for the Efficacy and Safety of Statin Therapy. Lancet 2016, 388, 2532–2561. 10.1016/S0140-6736(16)31357-5. [DOI] [PubMed] [Google Scholar]
  21. Novozhilov Y. V.; Dorogov M. V.; Blumina M. V.; Smirnov A. V.; Krasavin M. An Improved Kilogram-Scale Preparation of Atorvastatin Calcium. Chem. Cent. J. 2015, 9, 7. 10.1186/s13065-015-0082-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Li F.; Jiang W.; Czarnik A. W.; Li W. Combinatorial Synthesis of Deuterium-Enriched Atorvastatin. Mol. Diversity 2016, 20, 453–459. 10.1007/s11030-015-9655-6. [DOI] [PubMed] [Google Scholar]
  23. Dias L. C.; Vieira A. S.; Barreiro E. J. The Total Synthesis of Calcium Atorvastatin. Org. Biomol. Chem. 2016, 14, 2291–2296. 10.1039/C5OB02546J. [DOI] [PubMed] [Google Scholar]
  24. Baumann M.; Baxendale I. R.; Ley S. V.; Nikbin N. An Overview of the Key Routes to the Best Selling 5-Membered Ring Heterocyclic Pharmaceuticals. Beilstein J. Org. Chem. 2011, 7, 442–495. 10.3762/bjoc.7.57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Roth B. D.The Discovery and Development of Atorvastatin, A Potent Novel Hypolipidemic Agent. In Progress in Medicinal Chemistry; Elsevier, 2002; Vol. 40, pp 1–22, DOI: 10.1016/S0079-6468(08)70080-8. [DOI] [PubMed] [Google Scholar]
  26. Butler D. E.; Le T. V.; Millar A.; Nanninga T. N.. Process for the Synthesis of (5R)-1,1-Dimethylethyl-6-cyano-5-hydroxy-3-oxohexanoate. U.S. Patent US5155251A, 1992, no. 19.
  27. Knorr L. Synthese von Furfuranderivaten Aus Dem Diacetbernsteinsäureester. Ber. Dtsch. Chem. Ges. 1884, 17, 2863–2870. 10.1002/cber.188401702254. [DOI] [Google Scholar]
  28. Paal C. Ueber Die Derivate Des Acetophenonacetessigesters Und Des Acetonylacetessigesters. Ber. Dtsch. Chem. Ges. 1884, 17, 2756–2767. 10.1002/cber.188401702228. [DOI] [Google Scholar]
  29. Kawato Y.; Iwata M.; Yazaki R.; Kumagai N.; Shibasaki M. A Simplified Catalytic System for Direct Catalytic Asymmetric Aldol Reaction of Thioamides; Application to an Enantioselective Synthesis of Atorvastatin. Tetrahedron 2011, 67, 6539–6546. 10.1016/j.tet.2011.05.109. [DOI] [Google Scholar]
  30. Roth B. D.; Blankley C. J.; Chucholowski A. W.; Ferguson E.; Hoefle M. L.; Ortwine D. F.; Newton R. S.; Sekerke C. S.; Sliskovic D. R.; Wilson M. Inhibitors of Cholesterol Biosynthesis. 3. Tetrahydro-4-Hydroxy-6-[2-(1H-Pyrrol-1-Yl)Ethyl]-2H-Pyran 2-One Inhibitors of HMG-CoA Reductase. 2. Effects of Introducing Substituents at Positions Three and Four of the Pyrrole Nucleus. J. Med. Chem. 1991, 34, 357–366. 10.1021/jm00105a056. [DOI] [PubMed] [Google Scholar]
  31. Brower P. L.; Butler D. E.; Deering C. F.; Le T. V.; Millar A.; Nanninga T. N.; Roth B. D. The Synthesis of (4R-Cis)-1,1-Dimethylethyl 6-Cyanomethyl-2,2-Dimethyl-1,3-Dioxane-4-Acetate, a Key Intermediate for the Preparation of CI-981, a Highly Potent, Tissue Selective Inhibitor of HMG-CoA Reductase. Tetrahedron Lett. 1992, 33, 2279–2282. 10.1016/S0040-4039(00)74189-X. [DOI] [Google Scholar]
  32. Baumann K. L.; Butler D. E.; Deering C. F.; Mennen K. E.; Millar A.; Nanninga T. N.; Palmer C. W.; Roth B. D. The Convergent Synthesis of CI-981, an Optically Active, Highly Potent, Tissue Selective Inhibitor of HMG-CoA Reductase. Tetrahedron Lett. 1992, 33, 2283–2284. 10.1016/S0040-4039(00)74190-6. [DOI] [Google Scholar]
  33. Roth B. D.Trans-6-[2-(3- or 4-Carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one Inhibitors of Cholesterol Synthesis. U.S. Patent US 4,681,893 C1, 1987.
  34. Sagyam R. R.; Padi P. R.; Ghanta M. R.; Vurimidi H. An Efficient Synthesis of Highly Substituted Pyrrole and Bis Pyrrole Derivatives. J. Heterocycl. Chem. 2007, 44, 923–926. 10.1002/jhet.5570440429. [DOI] [Google Scholar]
  35. Pandey P.; Srinivasa Rao T. An Efficient Synthesis of N3,4-Diphenyl-5-(4-Fluorophenyl)-2-Isopropyl-1H-3-Pyrrolecarboxamide, a Key Intermediate for Atorvastatin Synthesis. Bioorg. Med. Chem. Lett. 2004, 14, 129–131. 10.1016/j.bmcl.2003.10.019. [DOI] [PubMed] [Google Scholar]
  36. Lopchuk J. M.; Gribble G. W. Total Synthesis of Atorvastatin via a Late-Stage, Regioselective 1,3-Dipolar Münchnone Cycloaddition. Tetrahedron Lett. 2015, 56, 3208–3211. 10.1016/j.tetlet.2014.12.104. [DOI] [Google Scholar]
  37. Keating T. A.; Armstrong R. W. Postcondensation Modifications of Ugi Four-Component Condensation Products: 1-Isocyanocyclohexene as a Convertible Isocyanide. Mechanism of Conversion, Synthesis of Diverse Structures, and Demonstration of Resin Capture. J. Am. Chem. Soc. 1996, 118, 2574–2583. 10.1021/ja953868b. [DOI] [Google Scholar]
  38. van der Heijden G.; Sjaak Jong J. A. W.; Ruijter E.; Orru R. V. A. 2-Bromo-6-Isocyanopyridine as a Universal Convertible Isocyanide for Multicomponent Chemistry. Org. Lett. 2016, 18, 984–987. 10.1021/acs.orglett.6b00091. [DOI] [PubMed] [Google Scholar]
  39. Chen X.; Xiong F.; Chen W.; He Q.; Chen F. Asymmetric Synthesis of the HMG-CoA Reductase Inhibitor Atorvastatin Calcium: An Organocatalytic Anhydride Desymmetrization and Cyanide-Free Side Chain Elongation Approach. J. Org. Chem. 2014, 79, 2723–2728. 10.1021/jo402829b. [DOI] [PubMed] [Google Scholar]
  40. Gao J.; Guo Y. H.; Wang Y. P.; Wang X. J.; Xiang W. S. A Novel and Efficient Route for the Preparation of Atorvastatin. Chin. Chem. Lett. 2011, 22, 1159–1162. 10.1016/j.cclet.2011.04.016. [DOI] [Google Scholar]
  41. Müller M. Chemoenzymatic Synthesis of Building Blocks for Statin Side Chains. Angew. Chem., Int. Ed. 2005, 44, 362–365. 10.1002/anie.200460852. [DOI] [PubMed] [Google Scholar]
  42. Baldoli C.; Giannini C.; Licandro E.; Maiorana S.; Zinzalla G. A Thymine-PNA Monomer as New Isocyanide Component in the Ugi Reaction: A Direct Entry to PNA Dimers. Synlett 2004, 2004, 1044–1048. 10.1055/s-2004-822886. [DOI] [Google Scholar]
  43. Baldoli C.; Maiorana S.; Licandro E.; Zinzalla G.; Perdicchia D. Synthesis of Chiral Chromium Tricarbonyl Labeled Thymine PNA Monomers via the Ugi Reaction. Org. Lett. 2002, 4, 4341–4344. 10.1021/ol026994a. [DOI] [PubMed] [Google Scholar]
  44. Maison W.; Schlemminger I.; Westerhoff O.; Martens J. Multicomponent Synthesis of Novel Amino Acid–nucleobase Chimeras: A Versatile Approach to PNA-Monomers. Bioorg. Med. Chem. 2000, 8, 1343–1360. 10.1016/S0968-0896(00)00066-3. [DOI] [PubMed] [Google Scholar]
  45. Maison W.; Schlemminger I.; Westerhoff O.; Martens J. Modified PNAs: A Simple Method for the Synthesis of Monomeric Building Blocks. Bioorg. Med. Chem. Lett. 1999, 9, 581–584. 10.1016/S0960-894X(99)00024-4. [DOI] [PubMed] [Google Scholar]
  46. Fleige M.; Glorius F. α-Unsubstituted Pyrroles by NHC-Catalyzed Three-Component Coupling: Direct Synthesis of a Versatile Atorvastatin Derivative. Chem. - Eur. J. 2017, 23, 10773–10776. 10.1002/chem.201703008. [DOI] [PubMed] [Google Scholar]
  47. Estévez V.; Villacampa M.; Menéndez J. C. Concise Synthesis of Atorvastatin Lactone under High-Speed Vibration Milling Conditions. Org. Chem. Front. 2014, 1, 458–463. 10.1039/C4QO00052H. [DOI] [Google Scholar]
  48. Dömling A.Methods for Providing Intermediates in the Synthesis of Atorvastatin. World Patent WO2016122325A1, 2016.

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

ml8b00579_si_001.pdf (520.8KB, pdf)

Articles from ACS Medicinal Chemistry Letters are provided here courtesy of American Chemical Society

RESOURCES